CTOs on the Move

Bert Fish Medical Center

www.bertfish.com

 
Bert Fish Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Bert Fish Medical Center is based in New Smyrna Beach, FL. You can find more information on Bert Fish Medical Center at www.bertfish.com
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.bertfish.com
  • 401 Palmetto St
    New Smyrna Beach, FL USA 32168
  • Phone: 386.424.5000

Executives

Name Title Contact Details

Similar Companies

Stroops Fitness Ctr

Stroops Fitness Ctr is a Clearfield, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Montrose Counseling Center

Montrose Counseling Center is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PlushCare

PlushCare provides doctor`s visits from the comfort of your home, office, or wherever you`re located.

Midwest Health Care

Midwest Health Care is a Cape Girardeau, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.